Margie N. Sutton, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Director of Education, Cancer Systems Imaging, Diagnostic Imaging, UT MD Anderson, Houston, Texas
Assistant Professor, Cancer Systems Imaging, Diagnostic Imaging, UT MD Anderson, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, US, Cancer Biology, PhD |
| 2010 | The University of Texas at San Antonio, San Antonio, Texas, US, Chemistry, Biology, BS |
Postgraduate Training
| 2018-2022 | Research Fellowship, UT MD Anderson |
| 2017-2018 | Research Fellowship, UT MD Anderson |
Experience & Service
Faculty Academic Appointments
Instructor, Cancer Systems Imaging, Diagnostic Imaging, UT MD Anderson, 2022 - 2024
Administrative Appointments/Responsibilities
Director of Education, Cancer Systems Imaging, UT MD Anderson, 2024 - Present
Other Professional Positions
Postdoctoral Fellow, UT MD Anderson, 2018 - 2022
Research Scientist I, The University of Texas at San Antonio, San Antonio, TX, 2011 - 2011
Extramural Institutional Committee Activities
Faculty Affiliate, Keck Executive Committee for Gulf Coast Consortia, UT MD Anderson, 2025 - Present
Member, Faculty Senate, UT MD Anderson, 2022 - 2025
Honors & Awards
| 2022 | Linda K. Manning Ovarian Cancer Endowed Research Award, UT MD Anderson |
| 2020 - 2025 | Ruth L. Kirchstein Postdoctoral Individual Research Service Award (F32) Fellow, National Cancer Institute |
| 2020 | Harold C. and Mary L. Dailey Endowed Fellowship Recognition of Research Excellence, UT MD Anderson |
| 2019 | Diane Denson Tobola Endowed Fellowship in Ovarian Cancer Research, UT MD Anderson |
| 2018 | AACR Scholar-in-Training Award Annual Meeting, American Association for Cancer Research |
| 2017 | Clyde H. Wright Memorial Fund Travel Award, Department of Experimental Therapeutics |
| 2017 | Ann and Sol Schreiber Mentored Investigator Award, Ovarian Cancer Research Fund Alliance |
| 2016 | Shohrae Hajibashi Memorial Leadership Award, UTHealth Houston |
| 2013 - 2016 | NIH CCTS TL1 Fellow in Translational Research, GSBS Houston |
| 2013 - 2014 | American Legion Auxiliary Fellow in Cancer Research, GSBS Houston |
| 2013 | Thomas F. Burks Outstanding Leadership and Service Award, UTHealth Houston |
| 2010 | Phi Beta Kappa, Phi Beta Kappa Society |
| 2009 | Jane Findling Award, The University of Texas at San Antonio |
| 2007 - 2010 | Dean's List, The University of Texas at San Antonio |
| 2007 - 2010 | Campus Honors College, The University of Texas at San Antonio |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. From Drug Screen to Therapeutic Target: The Potential of Statins as 4lg-B7-H3-depenent Immune Modulators. Invited. Texas A&M University Drug Discovery Center and Rice University SynthesisX Center. Houston, TX, US.
- 2023. Panel Discussion: Imaging Immune Response. Conference. The University of Texas MD Anderson Cancer Center.
- 2023. Statins Inhibit Onco-dimerization of B7-H3: A Link Between Cholesterol Metabolism and Tumor Immunobiology. Invited. 12th Annual Metabolism in Cancer Symposium 2023.
- 2020. In Vivo Fluorescence Imaging Reveals Target Engagement of Mutation Specific RAS-inhibitor, ARS-1620. Invited. Recognition of Research Excellence, Trainee Research Day.
- 2016. Autophagy and Cancer dormancy: strategies to eliminate dormant drug resistant cancer cells. Invited. Autophagy in Health and Disease. Houston, TX, US.
- 2014. Panel Discussion Leader: Applying for Funding. Conference. American Physician Scientists Association South Regional Meeting. Houston, TX, US.
National Presentations
- 2027. Systems-Level Insights into Response and Resistance: B-Radioligand Therapy for Cancer Cures and Immune Engagement. Invited. AACR Special Conference: Cancer Biology-Informed Radioligand Therapy. San Diego, California, US.
- 2026. Immune State Remodeling Following 90Y-DOTA-MIL33B β-Radioligand Therapy Reveals Enrichment of TCF1/7+ CD4+ T-Cells In Responding Tumors. Invited. Gordon Research Conference: Radionuclide Theranostics. Newry, Maine, US.
- 2025. Accelerating Therapeutic Discovery through Spatial Mapping, Molecular Imaging and ML for Therapeutic Libraries. Invited. AI x Tech in Drug Discovery. Boston, MA, US.
- 2017. DIRAS3 disrupts RAS multimeters at the plasma membrane. Invited. The Second RAS Initiative Symposium Sponsored by the National Cancer Institute. Frederick, MD, US.
International Presentations
- 2023. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Invited. United Scientific Group. N/A, US.
Selected Publications
Peer-Reviewed Articles
- Sutton MN, Muzzioli R, Pisaneschi F, Gammon S, Napoli A, Puglielli R, McIntosh L, Tereshatov E, Tabacaru G, Schultz S, McCann L, Burns J, Yennello S, Piwnica-Worms D. Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy. ACS Chemical Biology, 2026. PMID: 42504699.
- Glazer SE, Sutton MN, Yang P, Pisaneschi F, Sebastian M, Gammon ST, Piwnica-Worms D. Anti-cancer immune priming with beta-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3. Theranostics 16(10):5370-5392, 2026. e-Pub 2026. PMID: 41993624.
- Gray JP, Bildik G, Kim HN, Sutton MN, Wang J, Osuji AO, Batistatou N, Yang H, Mao W, Tan Z, Gasmi-Seabrook GMC, Liu J, Hancock JF, Marshall CB, Kritzer JA, Ikura M, Bast RC Jr, Millward SW, Lu Z. DIRAS3-derived cyclic peptides disrupt KRAS-RAF interaction and KRAS nanoclustering, suppressing KRAS-driven pancreatic and ovarian tumors. iScience 28(11):113686, 2025. e-Pub 2025. PMID: 41244592.
- Sutton MN, Glazer SE, Al Zaki A, Napoli A, Yang P, Bhosale P, Liu J, Gammon ST, Piwnica-Worms D. Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3. bioRxiv, 2024. e-Pub 2024. PMID: 39763965.
- Sutton MN, Glazer SE, Al Zaki A, Napoli A, Yang P, Bhosale P, Liu J, Gammon ST, Piwnica-Worms D. Statins Inhibit Onco-dimerization of B7-H3. bioRxiv, 2024. e-Pub 2024.
- SE Glazer, MN Sutton, P Yang, F Pisaneschi, M Sebastian, ST Gammon, D Piwnica-Worms. Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3. bioRxiv, 2024. e-Pub 2024.
- Sutton MN, Glazer SE, Muzzioli R, Yang P, Gammon ST, Piwnica-Worms D. Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling. Commun Biol 7(1):21, 2024. e-Pub 2024. PMID: 38182652.
- Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568603.
- Engel BJ, Paolillo V, Uddin MN, Gonzalez KA, McGinnis KM, Sutton MN, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed by Multi-modal Imaging. Cancers, 2023. e-Pub 2023.
- Sutton MN, Gammon ST, Muzzioli R, Pisaneschi F, Radaram B, Yang P, Piwnica-Worms D. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Molecular Imaging and Biology 24(3):498-509, 2021. e-Pub 2021. PMID: 34905147.
- Rao Y, Gammon ST, Sutton MN, Zacharias NM, Bhattacharya P, Piwnica-Worms D. Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner. J Biol Chem 297(1):100775, 2021. e-Pub 2021. PMID: 34022218.
- Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
- Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
- Sutton MN, Lu Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Liang X, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC. DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Rep 29(11):3448-3459.e6, 2019. e-Pub 2019. PMID: 31825828.
- Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prev Res (Phila) 12(6):391-400, 2019. e-Pub 2019. PMID: 30967390.
- Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 125(8):1267-1280, 2019. e-Pub 2019. PMID: 30620384.
- Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31052266.
- Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, Bast RC. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers (Basel) 11(4), 2019. e-Pub 2019. PMID: 31003488.
- Sutton MN, Yang H, Huang GY, Fu C, Pontikos M, Wang Y, Mao W, Pang L, Yang M, Liu J, Parker-Thornburg J, Lu Z, Bast RC. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy 14(4):637-653, 2018. e-Pub 2018. PMID: 29368982.
- Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC, Millward SW. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16(1):824, 2016. e-Pub 2016. PMID: 27784287.
- Morgado M, Sutton MN, Simmons M, Warren CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC, Carson DD. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget 7(12):14871-84, 2016. e-Pub 2016. PMID: 26918940.
- Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836, 2015. e-Pub 2015. PMID: 26247722.
- Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC. ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21(8):1275-89, 2014. e-Pub 2014. PMID: 24769729.
Review Articles
- Bildik G, Liang X, Sutton MN, Bast RC, Lu Z. DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. Mol Cancer Ther 21(1):25-37, 2022. e-Pub 2022. PMID: 34667114.
Abstracts
- Sutton MN, Ajlan Al Zaki, Ping Yang, Xudong Qui, Jorge Delacerda, Molliane Murray, Lauren Colbert, Mitra Devarati, Seth Gammon, David Piwnica-Worms. 219 Multi-Dimensional Immune Reprogramming for Early Interception of Radiation-Induced Fibrosis of the Skin. JID 145(11), 2025. e-Pub 2025.
- Sutton MN, Al-Zaki A, Yang P, Qui X, Delacerda J, Murray M, Colbert L, Devarati M, Gammon S, Piwnica-Worms D. 219 Multi-Dimensional Immune Reprogramming for Early Interception of Radiation-Induced Fibrosis of the Skin, 2025. e-Pub 2025.
- Al Zaki A, Sutton MN, Rehman A, Cuong Le C, Gammon ST, Napoli A, Yang P, Saini N, Ahmed S, Issa G, Kebriaei P, Davies M, Shpall E, Varghese J, Flynt L, Neelapu S, Piwnica-Worms D. Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy 144(1):3428, 2024. e-Pub 2024.
- R Muzzioli, F Pisaneschi, S Gammon, Sutton MN, A Napoli, L McIntosh, E Tereshatov, G Tabacaru, S Schultz, L McCann, J Burns, S Yennello, D Piwnica-Worms. O-36 - Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Radioligand Therapy Applications 126-127, 2023. e-Pub 2023.
- Glazer SE, Sutton MN, Yang P, Pisaneschi F, Gammon ST, D Piwnica-Worms. A novel high affinity anti-B7H3 antibody selective for the 4Ig-B7H3 isoform when labeled with ytrrium-90 provides long term survivors for established radioresistant colorectal carcinoma when administered as a single-dose treatment 64(1):1021, 2023. e-Pub 2023.
- Glazer SE, Sutton MN, Yang P, Gammon ST, Piwnica-Worms D. Single Dose Treatment with a Novel Yttrium-90-labeled High Affinity Anti-B7-H3 Antibody Selective for the 4Ig-B7-H3 Isoform Provides Long Term Survivors for Established Radioresistant Colorectal Carcinoma 83(7):5036, 2023. e-Pub 2023.
- J Gray, G Bildik, Sutton MN, Y Zhou, S Millward, J Hancock, Z Lu, R Bast. Helical stapled peptides derived from DIRAS3 block KRAS dimerization and downstream MEK/ERK signaling in pancreatic and ovarian carcinomas 82(12):3599, 2022. e-Pub 2022.
- Gray JP, Bildik GE, Sutton MN, Zhou Y, Millward S, Hancock JF, Lu Z, Bast RC. Helical stapled peptides derived from DIRAS3 block KRAS dimerization and downstream MEK/ERK signaling in pancreatic and ovarian carcinomas. Cancer Research 82(12 Supplement), 2022. e-Pub 2022.
- Sutton MN, Glazer SE, Yang P, Gammon ST, Piwnica-Worms D. B7-H3 dimerization/multimerization provides oncogenic advantage while knockout of B7-H3 reduces tumorigenic burden, 2022. e-Pub 2022.
- Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast Jr RC. The Role of VEGF, IL-8 and IGF in Sustaining Autophagic DIRAS3-induced Dormant Ovarian Cancer Xenografts, 2019. e-Pub 2019.
- Sutton MN, Huang GY, Zhou J, Lu Z, Bast Jr RC. DIRAS3 (ARHI) is required for amino acid-mediated autophagy and nutrient deprivation in dormant ovarian cancers, 2018. e-Pub 2018.
- Sutton MN, Lu Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC. DIRAS3 (AHRI) blocks Ras/MAPK signaling by binding directly to Ras and disrupting Ras clusters, 2017. e-Pub 2017.
- Sutton MN, Lu Z, Yang H, Huang G, Wang Y, Mao W, Bast RC. DIRAS1 and DIRAS2 are novel ovarian cancer tumor suppressors that regulate cell growth, motility and autophagy, 2016. e-Pub 2016.
- Sutton MN, Lu Z, Li Y, Reger A, Hurwitz A, Palzkill T, Wahl G, Bast RC. DIRAS3 (AHRI) downregulates Ras/MAPK signaling via interaction and inhibition of Ras dimers, 2016. e-Pub 2016.
- Lu Z, Orozco AF, Yang H, Sutton MN, Bast RC. IL-8, VEGF, and IGF-1 play the important role in ARHI mediated-tumor dormancy in ovarian cancer, 2016. e-Pub 2016.
- Sutton MN, Lu Z, Bast RC. DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility and proliferation while regulating autophagy in ovarian cancer, 2015. e-Pub 2015.
- Lu Z, Sutton MN, Orozco AF, Wang Y, Mao W, Bast RC. Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment, 2015. e-Pub 2015.
- Lu Z, Orozco AF, Sutton MN, Wang Y, Mao W, Bast RC. IL8, VEGF and IGF-1 rescue ovarian cancer cells undergoing ARHI-mediated-autophagic cell death, 2015. e-Pub 2015.
- Morgado M, Sutton MN, Simmons M, Liu J, Lu Z, Papadppoulos PE, Bast RC, Carson DD. MC16/CA125, TNFa and IFN-y are co-expressed in malignant gynecologic neoplasms, 2015. e-Pub 2015.
- Huang GY, Lu Z, Sutton MN, Reger AS, Hurwitz A, Palzkill T, Kim C, Bast RC. AHRI induces autophagy in part by binding to the coiled domain of Beclin-1, monomerizing Beclin-1 dimers and displacing Bcl-2, 2015. e-Pub 2015.
- Bast RC, Sutton MN, Gomez S, Fu C, Pontrakis M, Lu Z. The role of the imprinted tumor suppressor gene DIRAS3 (ARHI) in regulating ovarian cancer cell growth, motility, autophagy and tumor dormancy, 2014. e-Pub 2014.
- Sutton MN, Lu Z, Bast RC. DIRAS family members inhibit cell growth and proliferation while inducing autophagy in human ovarian cancer, 2014. e-Pub 2014.
- Bast RC, Sutton MN, Wao W, Wang Y, Lu Z. Elimination of dormant ovarian cancer cells by targeting autophagy, 2014. e-Pub 2014.
- Sutton MN, Lu Z, Gomez S, Fu C, Bast RC. ARHI (DIAS3) downregulates Ras-MAPK signaling and inhibits transformation of NIH3T3 cells through direct interaction with GTP-bound Ras, 2014. e-Pub 2014.
- Morgado M, Sutton MN, Simmons M, Lu Z, Bast RC, Carson DD. Cytokine Stimulation and Rosiglitazone Antagonism of MUC16 Expression in Human Endometrial and Ovarian Epithelial Cell Lines, 2013. e-Pub 2013.
- Sutton MN, Fu C, Pontikos M, Lu Z, Bast RC. DIRAS family members inhibit cell growth and proliferation while inducing autophagy in human ovarian cancer, 2013. e-Pub 2013.
Book Chapters
- Sutton MN, Jackson LE. Barotrauma and Decompression Sickness. In: Encyclopedia of Otolaryngology, Head and Neck Surgery V2. Springer, 2026.
- Sutton MN, Lu Z, Bast RC. The role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy. In: Autophagy: Cancer, Other Pathogens, Inflammation, Immunity, Infection and Aging. 1st, 2014.
- Jackson LE, Sutton MN. Barotrauma and Decompression Sickness. In: Encyclopedia of Otolaryngology, Head and Neck Surgery. Springer, 2013.
Patient Reviews
CV information above last modified August 14, 2026